OGN vs. GSK
Compare and contrast key facts about Organon & Co. (OGN) and GlaxoSmithKline plc (GSK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: OGN or GSK.
Correlation
The correlation between OGN and GSK is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
OGN vs. GSK - Performance Comparison
Key characteristics
OGN:
-0.72
GSK:
-0.21
OGN:
-0.90
GSK:
-0.12
OGN:
0.89
GSK:
0.99
OGN:
-0.44
GSK:
-0.19
OGN:
-1.19
GSK:
-0.34
OGN:
25.07%
GSK:
16.11%
OGN:
41.34%
GSK:
26.51%
OGN:
-69.56%
GSK:
-55.21%
OGN:
-63.31%
GSK:
-15.61%
Fundamentals
OGN:
$3.13B
GSK:
$75.93B
OGN:
$3.33
GSK:
$1.65
OGN:
3.64
GSK:
22.73
OGN:
0.49
GSK:
2.42
OGN:
6.62
GSK:
4.19
OGN:
$4.78B
GSK:
$24.01B
OGN:
$2.76B
GSK:
$16.98B
OGN:
$1.17B
GSK:
$5.14B
Returns By Period
In the year-to-date period, OGN achieves a -16.73% return, which is significantly lower than GSK's 11.89% return.
OGN
-16.73%
-17.06%
-26.31%
-29.42%
N/A
N/A
GSK
11.89%
-2.30%
2.01%
-4.78%
1.57%
2.53%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
OGN vs. GSK — Risk-Adjusted Performance Rank
OGN
GSK
OGN vs. GSK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Organon & Co. (OGN) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
OGN vs. GSK - Dividend Comparison
OGN's dividend yield for the trailing twelve months is around 9.18%, more than GSK's 4.15% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
OGN Organon & Co. | 9.18% | 7.51% | 7.77% | 4.01% | 1.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
GSK GlaxoSmithKline plc | 4.15% | 4.60% | 3.75% | 4.78% | 4.92% | 5.49% | 4.28% | 5.55% | 5.72% | 7.06% | 5.96% | 6.09% |
Drawdowns
OGN vs. GSK - Drawdown Comparison
The maximum OGN drawdown since its inception was -69.56%, which is greater than GSK's maximum drawdown of -55.21%. Use the drawdown chart below to compare losses from any high point for OGN and GSK. For additional features, visit the drawdowns tool.
Volatility
OGN vs. GSK - Volatility Comparison
Organon & Co. (OGN) has a higher volatility of 22.63% compared to GlaxoSmithKline plc (GSK) at 11.15%. This indicates that OGN's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
OGN vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Organon & Co. and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities